Ligand Pharma. Wer weiß genaueres? - 500 Beiträge pro Seite

[Megagigant]

Wer kann mir genaueres über diese Aktie sagen? Ist es
sinnvoll dort zu investieren? Wäre sehr dankbar über Antworten.

Danke Megagigant

[JoeUp]

Hallo,

im augenblick gibt es Kaufpreise!
Zur liegt ein Produkt zur Zulassung bei der NDA vor. Im Juni wird die
Zulassung erwartet!
Viel mehr unter www.ligand.com!
Man kann sich auch eine Mappe zusenden lassen!

Gruß JoeUp


**************

Wo ist eigentlich Profiteam, der 500% Puscher!!!!!!

[profiteam]

HIER, JoeUp !

Ligand hat in einem kalifornischen Analystencomment
ein weiteres StrongBuy erhalten.

Diese Info war eine Ausnahme - wir werden uns weiterhin bedeckt
halten, damit diese unwahren Bemerkungen wie "500%-Pusher" in Kürze
Lügen gestraft werden - mal sehen, ob du auch genug Rückrat besitzt
dich dann öffentlich zu entschuldigen, JoeUp.

Bis im NORDEN
Profiteam

[Lindwurm]

Hallo an alle,

Ligand Pharma ist führend im Forschungsbereich der Androgen-Störungen und Fehlfunktionen wie z.B. Osteoporose und Störungen der Sexualfunktion (Post-menopause).
Das Unternehmen hat heute angekündigt, mit dem neuen Medikament LGD2226 die ersten vorklinischen Versuche am Menschen einzuleiten. In zuvor durchgeführten Tierversuchen konnte LGD2226 den Muskel- bzw. Knochenschwund merklich eindämmen und die Regeneration wieder in Bewegung bringen. Zusätzlich konnte das Medikament das Prostatawachstum (die häufigste Ursache für Prostatakrebs) eindämmen.

Bisherige Medikamente arbeiteten auf der Basis von Testosteron (=männliches Sexualhormon) und sterioder Androgene. Diese Hormone führten oftmals zu einer Überbeanspruchung der Leber und förderten Krankheiten wie Leberzirrhose und Lebervergiftungen.

Die Ergebnisse dieser vorklinischen Studie werden auf Kongressen und in Kliniken (USA, Tschechien, Kanada) im Zeitraum vom 26.04.00 bis 24.06.00 präsentiert.

------------------

Ich hoffe, das diese sehr positive Meldung (Ich habe einen Artikel von Business Wire übersetzt. Ich hoffe, die wichtigsten Passagen gut getroffen zu haben) verleiht dem Kurs ein wenig Auftrieb.

+Grüsse

[JoeUp]

Hallo Profiteam,

die Tatsache, daß Du Dich gleich gemeldet hast, reicht mir, um meine Unterstellung
zurückzunehmen! Mir war nur aufgefallen, daß zur des Anstiegs bis auf 26 € öfters
Postings von Dir kamen. Während des Rückgangs auf 17,50 € war nichts von Dir zu
hören! Also sorry!
Ich habe bei 18 € nachgekauft, nachdem ich mir noch einmal in Ruhe die Produkt-
pipeline und die Kooperationspartner angeschaut habe!
Und das gibt allen Anlaß zu einem bedeutenden Anstieg!!

Gruß JoeUp

[toothstone]

Geht in USA in Richtung 20. Schaut ganz gut aus. Wenn ich ich könnte, würde ich gerne nochmal nachlegen zu meinen 250.

[loserbaby]

an profiteam,
was ist mit den von dir empfohlenen PANAFON (917482)
da tut sich ja gleich gar nichts.(keine Werbung,Vodafon?)
Ich verkaufe morgen oder hast du paar gute infos

[traderdepot]

Kann mich den oben genannten Meinungen nur anschließen !
Top Unternehmen mit top Aussichten :-)
Ihr könnt ja auch meinen Beitrag zur Meinungsbildung verfolgen !
Ligand hält sich trotz der Baisse im Biotech Bereichs recht ordentlich und bietet hervorragende Einstiegschancen !

MfG
traderdepot

[Der Pharmer]

Eistiegschance nicht verpassen:



Quelle:

http://earnings.nasdaq-amex.com/earnings/analyst_recommendat…

[Der Pharmer]

Dies sind die letzten News von Ligand:

Kann vielleicht jemand kurz sagen, was das auf gut Deutsch bedeutet ?
(Danke im Voraus)

( BW)(CA-LIGAND-PHARM)(LGND) Ligand Advances LGD2226 to Human Development Track for Androgen-Related Disorders; Target Male Hormone Replacement, Male and Female Sexual Dysfunction and Osteoporosis

Business Editors/Health & Medical Writers
BIOWIRE2K

SAN DIEGO--(BW HealthWire)--March 21, 2000--Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) announced today that it has moved onto human development track a clinical candidate, LGD2226, that it believes represents the first selective androgen receptor modulator ("SARM") for the treatment of major androgen-related diseases and disorders, such as osteoporosis, male hormone replacement, male and female sexual dysfunction, and cachexia (wasting).
SARMs are a novel class of orally active non-steroidal molecules that target modulation of the androgen receptor. SARMs are designed to enhance the beneficial effects of androgen receptor activation while reducing or eliminating the undesired side effects, such as liver toxicity and increased risk of prostate cancer, associated with the use of currently marketed steroidal full androgen agonists.
"The strength of the LGD2226 pre-clinical data suggests the potential value of this novel SARM compound and is, in our opinion, a major breakthrough in the field of androgen therapy," said Andres Negro-Vilar, Senior Vice President of Research and Development, and Chief Scientific Officer. "The use of Ligand`s molecular and cellular approaches and our expertise in developing tissue-selective nuclear receptor modulators, combined with a strong proprietary position in human androgen receptor technology, enabled Ligand scientists to achieve this important scientific milestone."
In a series of comprehensive pre-clinical studies carried out in established animal models, LGD2226 dosed once daily in long-term studies was able to fully maintain muscle and bone mass at doses much lower than those of a comparator, fluoxymesterone, an orally active steroidal androgen. In those studies, LGD2226 at doses that were fully effective on bone and muscle had a significantly reduced impact on prostate growth. The ability to minimize or eliminate the concerns of increased prostate cancer risk associated with the use of steroidal androgens clearly represents an additional advantage. LGD2226 was also shown to restore sex behavior in an animal model that evaluates the activity of these agents in restoring or enhancing libido and sexual drive.
Current androgen therapies include testosterone, in injectible or transdermal delivery forms that limit its use and range of therapeutic applications, and oral steroidal androgens, such as fluoxymesterone. The use of oral androgens has been limited by the concerns of potential liver toxicity of 17-alkylated steroidal molecules and by the relatively low efficacy achieved with those molecules compared to testosterone.
LGD2226 is one of a family of molecules that Ligand is developing to address the multiple therapeutic applications of SARMs. As a result of their potential to build bone while preventing bone loss, these novel SARMs represent important new therapeutic opportunities for the treatment of both male and female osteoporosis. These agents also show distinct promise for the treatment of sexual dysfunction, not only in hypogonadal or elderly males but, importantly, in women. The combined activity of restoring sexual drive in postmenopausal women while providing anabolic activity in bone, alone or in combination with estrogen replacement therapy, would address a large unmet market need.
"Ligand`s leadership in the field of SARMs, combined with our already established strength in the field of Selective Estrogen Receptor Modulators (SERMs), positions the company at the forefront of innovation and advanced product development in broad therapeutic areas of women`s and men`s health, such as hormone replacement, osteoporosis, cardiovascular disease, breast and prostate cancer, and sexual disorders," said Chairman, President and CEO David E. Robinson. "LGD2226 is the result of Ligand`s substantial investment over the past five years in the androgen field and holds potential to be one of Ligand`s future big drugs for which we have retained worldwide rights. While the field of SARMs is so large as to require some partnering activities to capture its full potential, we intend to retain important molecule and field rights for ourselves as well."
Data on the utility and activity of SARMs and results of the pre-clinical studies with LGD2226 are expected to be presented by Ligand scientists at upcoming meetings, including at the National Institutes of Health workshop organized by the National Institute of Aging in Bethesda, MD, April 26-28; at the Federation of National European Menopause Societies in Prague, April 29-May 1; and at the Endocrine Society`s 82nd Annual Meeting in Toronto, June 21-24.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. In addition to the recently approved Targretin(R) capsules, Ligand had two drugs approved during 1999 for marketing in the U.S. -- ONTAK(R) and Panretin(R) gel -- that are being marketed through its specialty cancer and HIV-center sales force in the U.S. Targretin(R) gel is currently under review by the FDA for marketing approval in the U.S., and two additional oncology-related products -- Morphelan(TM) (licensed from Elan) and Panretin(R) capsules -- are in late-stage development. Ligand`s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IR) and Signal Transducers and Activators of Transcription (STATs).

Except for the historical information contained herein, this news release may contain certain forward looking statements by Ligand and actual results could differ materially from those described as a result of factors including, but not limited to the following. There can be no assurance that LGD2226 or any compound or product in the Ligand pipeline will be successfully developed for osteoporosis, hormone replacement therapy, male or female sexual dysfunction or any other indication; that results achieved in animal models will be supportive of regulatory filings required to initiate human clinical trials; that results from more advanced clinical trials will be consistent with earlier results; that regulatory filings will be made and regulatory approvals will be granted in a timely manner or at all; that LGD2226 or any other Ligand product will be accepted by physicians for prescribing, by patients for use and by insurance companies / agencies for reimbursement; that Ligand will retain any or all of its rights to LGD2226 or license any of its rights to SARMs to a collaborative partner; that Ligand and/or its collaborative partners will successfully develop potential products; or that Ligand will be able to hire and retain qualified personnel. Additional information concerning these and other factors affecting Ligand`s business can be found in press releases as well as in Ligand`s public periodic filings with the Securities and Exchange Commission, available at our website at http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

[Goggo_X]

hallooooooo......

wo seid Ihr denn alle hin. Ich habe lange nichts neues zu Ligand gefunden. Habt Ihr irgendwelche Neuigkeiten? Wo geht es hin?

[Der Pharmer]

Hallo Goggo,

Ist doch klar, wo`s hingeht:

Nach der allgemeinen Konsolidierung geht`s wieder nach oben !!!

Also im schlimmsten Fall noch bis zur 200-d Linie bei ca. 12$,
dann evtl. Seitwärtsbewegung, dann erneute Rallye mit Kursziel 50$
(laut Zürich Club)



Zum Ausstieg ist`s zu spät, jetzt heißt`s durchhalten !!

Wir srechen uns im Herbst wieder !

[Lindwurm]

Hallo Pharmer,

Ich habe den Artikel, den du hier gepostet und um dessen Übersetzung du gebeten hast, im 4. posting von oben schon kurz zusammengefasst.

+Grüsse

[Der Pharmer]

Danke an Lindwurm !

Was meinst du, wird die 200-d Linie halten ???

[Lindwurm]

Hallo Pharmer,

Zur 200-Tage Linie:

Sie liegt ziemlich genau bei 13$, dort gibt es eine starke Unterstützungslinie, die durch den Kursverlauf Ende Dezember und Anfang Februar geprägt wurde.
Ich bin der Überzeugung (Hoffnung?), dass diese Linie halten wird, denn das Gröbste dürfte meiner Meinung nach überstanden sein. Laut letzter Pressemitteilung werden die Ergebnisse der vorklinischen Studien über LGD2226 ja ab dem 26.04.00 präsentiert.
Zudem habe ich mich ja schon die letzten Tage gefragt, wer bei diesen Kursen überhaupt noch verkauft!.

Aus Sicht der Candlesticks würde ich auf ein Downside Gap schliessen. (die ersten zwei Tage davon)

Kurzfristig deutet das auf ein Beibehalten des Abwärtstrends hin, jedoch darf man in diesen Tagen die sehr starke psychologische Komponente des Marktes nicht übersehen. (Detail am Rande: Der Kursrutsch am Freitag war grösser als der am Schwarzen Freitag im Jahr 1929).
Ich rechne damit, dass die nächste Woche noch ein wenig verhalten verlaufen wird, aber danach sollte es wieder bergauf gehen.

Falls jemand Lust hat, sich über Candlestick-Charts zu informieren, ich habe meine Homepage gerade um diesen Punkt erweitert. Kritik und Anregung jederzeit willkommen!.

http://members.aon.at/nasdaq/

+Grüsse

[Lindwurm]

Hallo an alle,

Nun, ein Gap ist sich leider nicht ausgegangen. So wie es derzeit aussieht, geht sich nur ein Hammer aus -- trotzdem ein gutes Zeichen.
Immerhin hat die 12$-Linie gehalten!.

+Grüsse

[glocksi]

Hallo Leute,

was ist nun aus Eurem so tollen Krebsmittelchen geworden?
War es doch nur ein gepushe von Euch?

[Lindwurm]

Hallo Glocksi,

Hier nochmal ein Auszug aus meinem Posting vom 22.03.00 (4.Posting in diesem Thread)

Das Unternehmen hat heute angekündigt, mit dem neuen Medikament LGD2226 die ersten vorklinischen Versuche am Menschen einzuleiten. Die Ergebnisse dieser vorklinischen Studie werden auf Kongressen und in Kliniken (USA, Tschechien, Kanada) im Zeitraum vom 26.04.00 bis 24.06.00 präsentiert.

..warten wir´s ab!
+Grüsse

[Goggo_X]

Hallo Leute,
was wird denn jetzt mit ligand? hat jemand neue erkenntnisse? es ist mächtig ruhig geworden in der letzten zeit.

ist hier noch jemand, der sich weiterhin für diese aktie interessiert?

Gruß

Goggo

[Der Pharmer]

Keine Angst, Goggo,

Die 200d-Linie hat gehalten (bei 12$)!

Wenn du Geduld hast, wirst du die nächste Rallye im Herbst/Winter
miterleben.

Ich hab im Oktober 99 bei 7 Euro gekauft und werde erst
steuerfrei wieder verkaufen, mit engen Stopp-Loss bei der nächsten
Hausse !!!

Kursziel laut Zürich Club ist 50 $ !!!!

[traderdepot]

Hey Pharma !
Kannst Du die Empfehlung mit Kursziel 50 Euro mal posten ?
Bin bei 22,50 Euro rein und noch völlig von Ligand überzeugt !!

Danke
Traderdepot

http://www.maju.de/Traderdepot/index.html

[RCZ]

vom 3.5.


Capsules Show Positive Results in Moderate to Severe Plaque Psoriasis; Targretin Capsules Also Effective in Treating All Stages Of CTCL

SAN DIEGO--(BW HealthWire)--May 3, 2000--Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) announced today that abstracts published in the Journal of Investigative Dermatology and to be presented in Chicago at the Society of Investigative Dermatology`s (SID) 61st Annual Meeting (May 10-14) reported (1) results of Phase II clinical trials of Targretin(R) capsules to treat patients with moderate to severe plaque psoriasis, (2) results of two Phase II-III clinical trials of Targretin(R) capsules to treat patients with refractory or persistent CTCL, and (3) the development of a composite assessment method for evaluating CTCL.

Targretin capsules therapy was approved by the Food and Drug Administration (FDA) in December 1999 and is marketed in the U.S. by Ligand Pharmaceuticals for once-daily oral administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy.

"The results of studies presented at the SID Annual Meeting demonstrate the monotherapy activity of Targretin capsules in CTCL and, most recently, psoriasis," said Steven D. Reich, M.D., Ligand Senior Vice President, Clinical Research. "It is particularly encouraging that the studies of skin changes at the microscopic level by immunohistochemical techniques, as described by Dr. Jurgen Smit, confirm therapeutic benefits for patients suffering from psoriasis. Dr. Madeleine Duvic`s presentation summarizes the clinical information in patients with CTCL that helped gain FDA approval of Targretin capsules in December 1999. The composite assessment for evaluating CTCL presented by Dr. Patricia Myskowski is an important advance to clinical research in patients with CTCL as it provides a firm basis for determining objective response rates in a disease that is notoriously hard to evaluate.

"Ligand will continue its clinical program to expand the safety and efficacy of Targretin capsules in CTCL and psoriasis as well as other cancer and benign disease indications. It is expected that a new Phase II multi-center trial to further explore safety, efficacy and dose of Targretin capsules in psoriasis will be initiated in the U.S. as a result of this positive initial trial."

Phase II Clinical Trials in Psoriasis


A multi-center dose-ranging Phase II clinical trial to evaluate activity and safety of Targretin capsules in non-oncologic doses was conducted in 37 patients with moderate to severe plaque psoriasis. Patients typically had three to six prior therapies which commonly included corticosteroids, Vitamin D derivatives, PUVA and RAR retinoids. Jurgen Smit, M.D., University Hospital Nijmegen, Nijmegen, The Netherlands, reported an interim analysis of three of the four dose groups. In these three groups, Targretin capsules achieved at least 50% improvement in up to 46% of patients after 12 to 24 weeks of therapy. Data from the 3 mg/kg/day panel are pending.

Percent of Patients with Moderate to Severe Psoriasis
Who Achieved At Least 50% Improvement with Targretin Capsules Therapy


Dose Plaque Physician`s Global Psoriasis Area and
milligrams per Elevation Assessment (PGA) Severity Index (PASI)
kilogram of (PEL)(1) score
body weight
per day

0.5 38% 46% 31%
(13 patients)

1 25% 42% 25%
(12 patients)

2 50% 50% 25%
(12 patients)

3 Analysis pending Analysis pending Analysis pending
(12 patients)

(1) At least two-grade improvement on a five-point scale.


"Psoriasis is a chronic skin disease that requires sequential therapies as the disease progresses and may become drug resistant," said Dr. Smit. "New treatments are required and Targretin capsules appear to be a promising new candidate for psoriasis therapy. The results of our study suggest both clinical activity and changes in skin of immunohistochemical markers that are associated with improvement of the disease. Based on the positive results of this study, additional clinical trials with Targretin capsules alone and in combination with other therapies are warranted in patients with psoriasis, in order to find the profile of clinical efficacy and its side effects." Dr. Smit will discuss the interim results of this trial on Friday, May 12, at 9:00 a.m.

Immunohistochemical studies based on skin biopsies showed changes in cellular markers that were supportive of the clinical observations of improvement in psoriasis, and demonstrated that bexarotene was capable of reducing cell proliferation and hyperproliferation, as well as improving cell differentiation. The changes in cellular markers included statistically significant reductions in keratinocyte hyperproliferation and in overall dermal infiltrate, both key elements in the pathogenesis of psoriasis.

Targretin capsules therapy was generally well tolerated at all doses, with adverse events with an overall incidence greater than 10% and without regard to relatedness to Targretin capsules consisting of hyperlipidemia (57% incidence), pharyngitis (19%), asthenia (11%), and pruritus (11%). The side effect profile was dose-dependent, and more favorable at the lower doses. Notably absent or reduced were traditional retinoid toxicities such as dry mucous membranes, skin cracking, skin peeling, hair loss and sticky skin.

Psoriasis is a chronic immune-mediated skin disorder that affects more than 6.4 million people in the United States and appears to be slightly more prevalent among women than men. Approximately 150,000 new cases of psoriasis occur in the U.S. each year. Psoriasis is categorized into degrees of severity based on the amount of body surface area affected, which is useful in determining an individual`s treatment. Mild psoriasis is defined as affecting less than 2% of the body`s surface, moderate psoriasis is defined as affecting 2-10% and severe psoriasis is defined as affecting greater than 10%.

Advanced Stage CTCL Pivotal Trial Design and Results


Targretin capsules therapy was evaluated for safety and efficacy in two international open-label, multi-center, Phase II-III clinical trials of patients with refractory or persistent CTCL of Tumor, Nodule, Metastasis (TNM) Stages I-IIA or TNM Stages IIB-IV. Patients had failed at least two CTCL therapies (for Stages I-IIA) or were refractory to at least one systemic anticancer therapy (IIB-IV). Response was determined using standard oncologic criteria for monthly evaluations by a Physician`s Global Assessment (PGA) of disease and a Composite Assessment (CA) of the sum of scores of five clinical signs of representative index lesions.

"Overall, 49% of patients (74 of 152) achieved response by PGA or CA," said Madeleine Duvic, M.D., Chief, Section of Dermatology, University of Texas MD Anderson Cancer Center. Dr. Duvic will present the results of the trials in an oral presentation at SID on May 12 at 8:48 a.m. "These trials show Targretin capsules to be an effective and well-tolerated oral treatment for patients with all stages of CTCL that has been refractory following prior systemic anti-cancer therapy.

"Cutaneous T-cell lymphoma is a chronic, highly symptomatic, debilitating malignancy of T-cells that infiltrate the skin. While there are multiple conventional therapies, most patients become refractory to them. With the efficacy, durability and manageable side effects profile of Targretin capsules as shown in these two studies, I would expect that Targretin capsules would be used at some point in almost all patients with CTCL. Targretin capsules therapy is convenient for patients as it does not require specialized equipment or frequent visits to health care facilities other than for laboratory monitoring of blood for side effects."

Data were analyzed for responses at the initial doses of 6.5 (15 patients), 300 (84 patients) and over 300 milligrams per square meter of body surface area per day (mg/m2/day). Based on the CA and PGA endpoints, 49% of patients achieved clinical complete response (CCR) or partial response (PR) of greater than 50% improvement to treatment at any dose.

Percent of CTCL Patients in Trial Who Achieved
Greater than 50% Improvement with Targretin Capsules Therapy

Initial Patients Patient CCR Median Duration
Dose Level Response of Rate
(mg/m2/day) Disease Control

300 84 48% 4% 299 days

over 300 53 59% 17% 385 days


Targretin capsules therapy was well tolerated, and side effects were mostly mild to moderate. Side effects experienced by more than 10% of patients at least possibly related to treatment at the 300 mg/m2/day dose level included hypertriglyceridemia, hypercholesteremia, central hypothyroidism, headache, weakness and leukopenia. However, the side effects were generally easily managed, often required concomitant therapy for elevated triglycerides and hypothyroidism, and were reversible upon discontinuing treatment. Among the other less frequent side effects were diarrhea, fatigue, liver function test abnormalities, rash, pancreatitis and itching. In general, side effects increased at doses greater than 300 mg/m2/day.

Composite Method for Evaluating CTCL


The Targretin capsules early and advanced stage studies provided the opportunity for the development of a composite assessment (CA) method for evaluating CTCL during clinical trials, as described by Patricia Myskowski, M.D., Associate Attending Physician, Dermatology Service, Memorial Sloan-Kettering Cancer Center in New York City. No widely used method exists for the measurement of CTCL disease severity or therapy response. The CA measured changes in five representative index lesions, combined with a consideration of cutaneous tumor and all extra-cutaneous systemic involvement (lymph nodes and visceral tumors), when present.

In two Phase II-III pivotal trials of Targretin capsules in early and advanced stage refractory CTCL, the CA endpoint was used effectively in conjunction with a PGA endpoint. At the optimal starting Targretin dose (300 mg per mg2 per day), the CA response rate was 36% and PGA was 50% in the early stage trial and CA was 27% and PGA was 48% in the advanced stage trial.

"CTCL tends to be multi-focal and may be heterogeneous in its presentation, so objective response criteria developed for solid tumors may not be applicable," noted Dr. Myskowski. "The composite assessment allows detailed evaluation of the signs and symptoms of selected lesions to reflect the overall response of the patient. Use of the CA response rate will allow cross-study comparison of results." Dr. Myskowski will discuss the methodology in a poster session on Wednesday, May 10, 7:30-9:30 p.m.

Ligand Pharmaceuticals Incorporated


Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. Ligand had three drugs approved during 1999 for marketing in the U.S. -- Targretin(R) capsules, ONTAK(R) and Panretin(R) gel -- that are being marketed through its specialty cancer and HIV-center sales force in the U.S. Targretin(R) gel is currently under review by the FDA for marketing approval in the U.S., and two additional oncology-related products -- Morphelan(TM) (licensed from Elan) and Panretin(R) capsules -- are in late-stage development. Ligand`s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IR) and Signal Transducers and Activators of Transcription (STATs).

This news release may contain certain forward looking statements by Ligand and actual results could differ materially from those described as a result of factors including, but not limited to, the following. There can be no assurance that final clinical data will be consistent with interim clinical data; Targretin capsules or any product in the Ligand pipeline will be successfully developed for psoriasis, or any other indication; regulatory filings will be made and regulatory approvals will be granted in a timely manner or at all; or that Targretin capsules or any other Ligand product will be accepted by physicians for prescribing, by patients for use and by insurance companies / agencies for reimbursement. Additional information concerning these and other factors affecting Ligand`s business can be found in press releases as well as in Ligand`s public periodic filings with the Securities and Exchange Commission, which are available via Ligand`s web site at http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Targretin(R) and Panretin(R) are registered trademarks of Ligand Pharmaceuticals Incorporated, and ONTAK(R) is a registered trademark of Seragen, Inc., a wholly owned subsidiary of Ligand. For prescribing information, call [phone].

CONTACT: Ligand Pharmaceuticals Incorporated
Paul V. Maier, 858/550-7573

[Der Pharmer]

Hallo RCZ,

Danke für die news vom 3.5., aber mein Biotech-English is very bad !!

Kann jemand in knappen deutschen Worten wiedergeben, was drin steht ??



Hallo traderdepot,

Schätze, du kennst den Zürich Club nicht.

Erscheint monatlich und gibt langfistige Empfehlungen
(Kursziele auf 3-5 Jahre) raus,
außerdem andere Finanz- und Steuertips.

Kann ich bedingt empfehlen, da sehr schlechtes Timing mit ihren
Empfehlungen (wer wirklich langfristig orientiert ist, dem macht das
natürlich nichts aus).

Kostet 150,-- DM im Quartal.

Die haben einige echte Perlen (vor allem im Biotech-Bereich)
sehr frühzeitig entdeckt und empfohlen.

Darunter eben Ligand, aber auch Axys Pharmaceuticals (Kursziel: 65$),
mit der ich von November 99 bis Ende Februar 2000 über 600% Gewinn
realisieren konnte.

Außerdem haben sie folgende Werte empfohlen:
Biogen schon in 9/97 zu 16-18$, Kursziel: 150$
Chiron in 9/98 zu 15-20$, Kursziel: 100$
Cytogen zu 6-8$, Kursziel: 30$
Icos Corp. zu 13,50$, Kursziel 90$
Millenium Pharm. in 12/97 zu 11-18$, Kursziel: 400$
Und ganz neu: Gliatech zu 15$, Kursziel: 50$

Aber der absolute Hammer war Ariad Pharmaceuticals:
Im Herbst noch unter 1$ und im Februar/März bei über 40$.
Wer da einen engen Stop-Loss gesetzt hat, konnte um 4000% !!!!!
realisieren.

Ich hab`s leider verpaßt, in Ariad zu investieren !!!
Solche Chancen sind selten !!

Anyway, der Zürich Club hat aber nicht nur gute, sondern auch
schlechte Werte empfohlen (ich denke jeder Börsenbrief hat mal
ne Niete dabei), wie zum Beispiel Agribiotech.
Da bin ich bei 3,40 Euro rein, wird seit einigen Monaten in
Deutschland nicht mehr gehandelt, sondern nur noch am OTC BB bei
Kursen um 0,05$.
Die Firma wird zerschlagen --> Totalverlust.

So kann`s auch gehn, wenn man keine Stop-Loss-Marken setzt.

Außerden sitzen die auf so langweilige Werte wie SKW Trostberg
(seit 5/99), die nicht in die Puschen kommen.

How ever, Ligand wird vom Zürich Club als nicht spekulativ eingestuft,
da Ligand in diesem Quartal die Gewinnzone erreichen wird,
viele Produkte in der Forschungspipeline hat und schon
10 Forschungsabkommen mit anderen Firmen abgeschlossen hat.

Das Kursziel von 50$ ist natürlich auf Sicht von 3-5 Jahren,
was nicht bedeutet, daß es nicht schon früher erreicht werden kann.

Ich schätze, daß wir die 50$ schon in der nächsten Hausse im
kommenden Herbst/Winter sehen.
Dann wird das Kursziel natürlich raufgesetzt !!

Traderdepot, wenn du bei 22,50 Euro rein bist,
dann bist du auf einen fahrenden Zug gesprungen, der am Prellbock
abgeprellt ist, oder bist du nach dem Top bei 27 Euro rein ??

Ligand wird schon wieder laufen, wenn das Börsen-Umfeld wieder stimmt.

In diesem Sinne,
Der Pharmer

[RCZ]

Hallo Pharmer

mein Biotech-English ist auch nicht das beste, auf der Hoffnung das sich jemand die Arbeit macht das auf Deutsch zusammenzufassen habe
ich das hier reinkopiert.

auf http://www.finance-online.de hab ich die
Zusammenfassung gefunden.

Ligand mit positivem Testergebnis


Ligand Pharmaceuticals (Nasdaq: LGND) hat heute die positiven Ergebnisse mit Targretin® Kapseln vorgestellt.

Die Ergebnisse einer Phase II Studie zur Behandlung von mittlere bis schwerer Schuppenflechte zeigten eine positive Wirkung des Medikaments. Targretin ist bereits seit Dezember 1999 zur Behandlung von hautähnlichen T-Zell Lymphgewebegeschwüren zugelassen.

LGND: 14,00 Dollar (+1,82%)


mehr News... Beitrag drucken Beitrag weiterempfehlen

04.05.00 21:01 -db- Partner:

[Millenium Bug]

Hallo,

wollte diesen Thread einfach nochmal hervorholen.
Gibt es was Neues???

Gruß
Bug

[JoeUp]

Hallo,

wollte diesen Thread einfach nochmal hervorholen.
Gibt es was Neues???

Gruß JoeUp

[RCZ]

Börse Online Ticker Talk vom 16.5.
Ligand Phamaceuticals (LGND) berichtet für 1Q mit 0,24 Dollar um 6 Cent schlechter als Wall Street prognostiziert hat. Der Umsatz steigt um 14% auf 11,7 Millionen Dollar.




auszug aus nasdaq.com (lgnd)

Ligand Reports First Quarter 2000 Results; Initiates Launch of Targretin Capsules While Burn Rate and Operating Losses Continue to Decline

SAN DIEGO--(BW HealthWire)--May 15, 2000--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported revenues for the first quarter ended March 31, 2000 of $11.7 million compared to $10.3 million for the same period in 1999, an increase of 13.5%. Net loss before debt conversion expense for the first quarter ended March 31, 2000, was $12.9 million ($0.24 per share) compared to the net loss of $14.6 million ($0.32 per share) for the same period in 1999, representing an improvement of 11.2% (or 25.0% per share). Including the one-time charge for debt conversion, net loss for the first quarter ended March 31, 2000 was $15.0 million ($0.28 per share) compared to the net loss of $14.6 million ($0.32 per share) for the same period in 1999.

As of March 31, 2000, Ligand had cash, cash equivalents, short-term investments and restricted cash of $49.4 million, an increase of $0.2 million from year-end 1999.

"Our burn rate and operating losses continue to decline as we expand our product sales and maintain tight controls on research, development and G&A expenses," said Paul V. Maier, Ligand Senior Vice President and Chief Financial Officer. "First quarter product revenues were our best to date and reflect the launch of Targretin(R) capsules which was approved by the FDA in late December 1999, solid growth of ONTAK(R) and a normalization of wholesale inventories of Panretin(R) gel. Sales continue to grow and we expect product sales in the subsequent quarters of 2000 to reflect the effect of the sales and marketing campaigns we launched during the first quarter for Targretin capsules and ONTAK as well as the expanded sales and marketing infrastructure put in place last year.

"We achieved important financial goals as well, through the maintenance of cash balances ($49.4 million), the sale of non-strategic assets (Marathon), and the strengthening of stockholders` equity through the additional ($20.0 million) note conversion by Elan."

Highlights of accomplishments during the first quarter of 2000:

-- Ligand sold the assets of Marathon Biopharmaceuticals Inc.,
the manufacturing subsidiary of Seragen, for $10.2 million.

-- Ligand was granted priority review by the FDA for the
Targretin gel NDA.

-- Ligand advanced to human development track LGD2226, a compound
targeting male hormone replacement, male and female sexual
dysfunction and osteoporosis.

-- Ligand and Organon entered into a collaboration for the
research and development of small molecule compounds with
potential effects for the treatment and prevention of
gynecological diseases through the progesterone receptor.

-- An affiliate of Elan Corporation plc ("Elan") accelerated
conversion of $20 million (issue price) of zero coupon
convertible notes into Ligand stock, increasing Ligand
stockholders` equity and reducing future non-operating
interest charges.

[Lindwurm]

Hallo an alle,

Hier die neueste Meldung bezüglich des neuen Medikaments "Pankretin Gel" (in Auszügen)

Longer-Term Use of Panretin Gel for Treatment of Patients with Cutaneous AIDS-Related Kaposi`s Sarcoma Improves Response Rate to 56%
Data Presented at the National Cancer Institutes` Fourth International AIDS Malignancy Conference

SAN DIEGO--(BW HealthWire)--May 17, 2000--
Ligand Pharmaceuticals Incorporated today announced study results showing that longer-term use of the Company`s Panretin® (alitretinoin) gel 0.1% substantially improves response rates in patients with cutaneous AIDS-related Kaposi`s sarcoma (KS). These results, based on long-term follow-up from the Company`s multicenter Phase III clinical trial, were presented in a poster session at the National Cancer Institutes` Fourth International AIDS Malignancy Conference in Bethesda, MD by Richard C. Yocum, M.D., Ligand`s Senior Medical Director, Clinical Research.

``The longer-term topical application of Panretin gel resulted in further, incremental benefit to patients during the follow-up of this Phase III trial after completion of the initial 12 weeks of treatment,`` noted Dr. Yocum.

``Overall response rate improved over the period to a 56% response rate. These data further demonstrate the significant and clinically meaningful efficacy of Panretin gel as a safe and effective treatment option for patients with cutaneous KS that can be self-applied at home without the need for frequent visits to health care providers.``

Der komplette Artikel unter:
http://biz.yahoo.com/bw/000517/ca_ligand_.html

+Grüsse

[traderdepot]

Danke für den Tip Pharma !!
Habe leider gerade erst wieder in diesem Tread gelesen.
Ich bin vor dem Top von 27 Euro aufgesprungen, nachdem ich den Kurs schon auf 7 Euro habe fallen sehen (war lange in meiner Watchlist).
Nachdem ich den Wert schon fast wieder vergessen hatte schaute ich wieder nach und habe mich erneut und zum ersten Mal richtig informiert.
Sehe die Aktie nach wie vor mit riesigem Potential.

Tschüs an "der Pharma" und den Rest ;-)

Traderdepot

[RCZ]

Ligand kooperiert mit Bristol Myers

Bristol-Myers Squibb (NYSE: BMY) und Ligand Pharmaceuticals (Nasdaq: LGND; WKN: 895777) haben heute den Abschluss eines kooperativen Forschungsabkommens bekanntgegeben.
Die beiden Unternehmen planten die gemeinsame Suche und Entwicklung von Wirkstoffen die selektiv an dem mineralocorticoid Rezeptor wirken. Dieser Rezeptor spielt eine kritische Rolle in verschiedenen Erkrankungen, insbesondere bei kardiovaskulären Erkrankungen wie Bluthochdruck und bei Herzkrankungen in Verbindung mit verstopften Blutgefäßen.

In dem Vertrag wurden nicht veröffentlichte Vorabzahlungen und bis zu 8,6 Millionen Dollar Forschungszahlungen an Ligand während der Zusammenarbeit bis April 2004 festgelegt.

Aktuell notiert Ligand mit 11,75 Dollar unverändert zum Vortag, Bristol Myers kann dagegen 0,65 Prozent dazugewinnen und notiert bei 57,88 Dollar.


quelle: www.finance-online.de

[JoeUp]

Hallo,

was gibt es neues bei Ligand!

Lt. Finanztreff beträgt der Umsatz in München per 11.45 h
11.500 Stck. bei anziehenden Kursen!!!

Gibt es Neuigkeiten???????????

JoeUp

[RCZ]

Ligand Pharms (LGND) erhält Zulassung den der FDA für Targretin, ein Gel zur Behandlung von frühzeitigem Lymphdrüsenkrebs. 08:48

www.Boerse-online.de

[kkhfjkvhrghf]

Hallo Leute,

weiß einer was mit der scheiß Aktie eigentlich los ist? Seit Wochen passiert da nichts mehr.
Denkt ihr das der Aktie noch Potential drinsteckt oder ist die Luft für die nächsten Monaten raus?
Bitte um Antworten!

MFG

[Checker.de]

Hallo Mike alter Zocker-Kollege !!!
Hab lange nichts mehr von dir gehört, aber wie
ich annehme bist du immer noch fett
im Geshäft.

wünsche profitable Geschäfte

hebe dehre oida ruah

[JoeUp]

Hallo,

was ist mit Ligand.
Gibt es bald Quartalszahlen.
Die Umsätze am Freitag waren ja umwerfend.
Für deutsche Verhältnisse!
Der Trend zeigt aufwärts!!
Wo ist Profiteam, der Seher?

Gruß JoeUp

[JoeUp]

Hallo,

was ist hier los. In USA gewaltige Umsätze, steigende Kurse.

In Germany auch steigende Kurse, aber Miniumsätze.

Hat keiner Interesse an der Aktie!!

JoeUp

[ErnieEarn]

hi Joe Up,

bin auch ein bischen drin in Ligand...vieleicht weißt Du es noch nicht, gestern gab es news, ob die dafür ausschlaggebend sind...???


Thursday August 31 4:43 PM ET
New Target Could Help Cholesterol Drugs

WASHINGTON (Reuters) - Chemical doorways into cells that stop them from taking in cholesterol might offer new targets for more precise cholesterol-lowering drugs, researchers said on Thursday.

The doorways are receptors known as LXR and FXR, and a drug in experimental development just might work to help control them, the researchers report in the journal Science.

David Mangelsdorf of the Howard Hughes Medical Institute at the University of Texas Southwestern Medical Center and colleagues, working with Tularik Corporation (NasdaqNM:TLRK - news) in San Francisco and Ligand Pharmaceuticals (NasdaqNM:LGND - news) in San Diego, said they had managed to switch off the absorption of cholesterol in mice.

The findings are a long way from helping people, Mangelsdorf warned.

``Although the results from these studies in mice are promising, there`s a long road ahead before these compounds can be considered for human clinical trials,`` he said in a statement.

But, writing in the journal Science, Mangelsdorf and colleagues said they might lead to a new generation of cholesterol-lowering drugs.

``Because we could show that these nuclear receptors had very direct and specific actions on cholesterol balance, they are excellent targets for drugs to affect cholesterol levels,`` said Mangelsdorf.

``Like many other such nuclear receptors, they are affected by drugs that can be taken orally and go right to the receptors.``

Scientists had been working with LXR and FXR for a while, but did not know how to activate them.

Ligand was working on a drug called LG268 to use against diabetes. The researchers found this compound activates RXR, a protein that is required for both LXR and FXR to work.

``Drugs like LG268 are especially promising because they are already being considered for clinical use for chemotherapy and diabetes,`` said Mangelsdorf. ``But there had been no reason to test the drug`s effect on cholesterol metabolism because nobody knew about LXR and FXR.``

When Mangelsdorf`s team gave LG268 to mice, it completely blocked their absorption of cholesterol. ``This was an astounding and dramatic effect,`` said Mangelsdorf.

They found the drug makes cholesterol less absorbable and also speeds up the transport of cholesterol out of the body.

The drug is not perfect. The body, sensing that no cholesterol is being absorbed, steps up its own production of cholesterol. The mice were fed mouse chow loaded with cholesterol, and while the drug prevented them from absorbing it, their bodies produced their own.

But Mangelsdorf said LG268 might be used as the basis for a better drug.

It might be used with the popular cholesterol-lowering statin drugs, which stop the body from making too much cholesterol but which do nothing to stop it from absorbing cholesterol in the diet.

``Using both kinds of drugs could actually produce a net loss of cholesterol in the body,`` said Mangelsdorf. ``By carefully monitoring drug dosages and cholesterol levels, you could essentially `dial-in` exactly the level you wanted a person`s cholesterol level to be.``


Email this story - (View

Gruß und beste Kurse
EE

[JoeUp]

Hallo,

schön Dich hier zu sehen, EE.

Gruß JoeUp

[JoeUp]

Hallo,

Ligand bewegt sich in letzter Zeit ziemlich nach oben. Hat sich um die 14$ gehalten
bei großen Umsätzen.und mich würde es nicht wundern, wenn bald mal mehr zu
sehen sein würde.

Wo ist eigentlich Profiteam, das Kursexplosionsmenetekel des Frühjahrs??

EE, immer noch gut gestimmt! Gibt es was Neues???

JoeUp

[JoeUp]

letzte News:
_______________________________________________________________________

SAN DIEGO--(BW HealthWire)--Oct. 17, 2000--Ligand Pharmaceuticals Incorporated
(Nasdaq:LGND) announced today that the European Commission has granted a Marketing
Authorization for Panretin(R) 0.1% gel (alitretinoin) for the topical treatment of cutaneous lesions in
patients with AIDS-related Kaposi`s sarcoma (KS). Panretin gel is the first approved topical therapy in
Europe for KS, the most common AIDS-related malignancy. The decision comes approximately three
months after the Committee for Proprietary Medicinal Products (CPMP) adopted a positive opinion
recommending Marketing Authorization. The U.S. Food and Drug Administration approved Panretin
gel in February 1999 for marketing in the United States.
"We are pleased with the Commission`s decision, which not only provides a new therapy for
European patients suffering from KS, but also advances the development of a European revenue stream
from our own products," said David E. Robinson, Ligand`s Chairman, President and CEO.
Ligand has agreements with Ferrer Internacional, S.A., to exclusively market and distribute Panretin
gel in Spain, Portugal, Greece, and Central and South America, and with Alfa Wassermann S.p.A. to
exclusively market and distribute Panretin gel in Italy. Ligand expects to complete additional agreements
in Europe to enable pan-European commercialization. In the United States, Panretin gel is marketed
through Ligand`s specialty sales force.

[winetrader]

Hallo an alle,

ich halte ebenfalls LGND und bin der Überzeugung, daß dieser Wert noch in keinster Weise erkannt wurde.
Eigentlich eine "kleine Perle", die schon Produkte am Markt hat! Lediglich die etwas schwache Zuwachsraten überzeugten in der jüngstn Vergangenheit nicht. Aber das werden viele momentan hoch bewertete Biotechs auch haben wenn sie aus der Forschung in die Vermarktung wechseln werden. Dies ist ein organisatorisch sehr schwieriger Schritt, der aber von LGND bald gemeistert sein wird.

winetrader

[JoeUp]

Danke an WT:
____________________________________________________________________________

Monday November 13, 7:09 pm Eastern Time
Press Release
Ligand Reports Third Quarter 2000 Results: Product Sales Up 129% and Net Loss per Share Down 33%
Ligand Reports Positive Data in Lung Cancer Patients Taking
Targretin Capsules, Receives Milestones On Advances in Collaborative

Product Pipeline

SAN DIEGO--(BW HealthWire)--Nov. 13, 2000--Ligand Pharmaceuticals Incorporated (Nasdaq:LGND - news) today reported revenues
of $12.1 million in the third quarter ended September 30, 2000, compared to $9.8 million in the third quarter of 1999, a 24% increase.
Net loss was $14.9 million (basic and diluted net loss of $0.26 per share) in the third quarter 2000, a decrease of $3.4 million or 18%
(or 33% per share) from the net loss of $18.3 million ($0.39 per share) in the third quarter 1999.

For the nine months ended September 30, 2000, revenues were $34.5 million compared to $28.5 million for the nine months ended
September 30, 1999, a 21% increase. In the same period, net loss was $46.3 million ($0.84 per share), a decrease of $5.5 million or
11% (or 24% per share) from the $51.9 million ($1.11 per share) net loss in the nine months ended September 30, 1999.

In announcing the results, Paul V. Maier, Ligand Senior Vice President and Chief Financial Officer, said, ``We are pleased with the
acceleration of growth of product revenues in the third quarter 2000 and with the positive new clinical data for Targretin capsules with
prospects to expand current marketed indications. Net product sales of $6.5 million in the third quarter 2000, up 32% over second
quarter 2000, reflect a doubling of sales of Targretin capsules to $2.4 million from $1.2 million in the second quarter 2000, the August
launch of our most recently approved product, Targretin® gel, with $0.7 million in sales, and a stable sales pattern for ONTAK®, with
$2.9 million in sales, each within the range of our expectations.

``We continue to develop our marketed products in additional larger-market indications, including non-small cell lung cancer
(Targretin capsules), breast cancer (Targretin capsules) and non-Hodgkin`s lymphoma (ONTAK). In August, we reported results of
clinical trials of Targretin capsules in NSCLC, suggesting that Targretin capsules may extend the survival of these critically ill
chemotherapy-treated patients. Similar patterns are emerging from other studies we have conducted in head and neck cancer, and
kidney cancer. After discussions with the FDA scheduled for later this quarter, we anticipate initiating pivotal Phase III trials of
Targretin capsules in NSCLC in 2001.

``We also enhanced the value of our corporate partner product pipeline and our royalty-based business during the third quarter 2000,``
Maier continued. ``In September, we recorded milestone payments from Pfizer for its launch of Phase III trials of lasofoxifene for the
treatment of women with post menopausal osteoporosis and from Lilly based on the advancement of major new compounds to treat
diabetes and cardiovascular disease.

``We continue to reduce net losses and cash burn by increasing revenues and maintaining tight controls on our expenses. During the
third quarter and the first nine months 2000 compared to the same periods in the prior year, increased investments in new product
launches were largely offset by declines in R&D and G&A expenses.``

Third Quarter and Nine Month 2000 Results

Product sales of $6.5 million in the third quarter ended September 30, 2000, grew 129% compared to sales for the same period in
1999 and 32% compared to the second quarter of 2000. The increase in third quarter sales reflected launch of Targretin capsules in
late January 2000 and Targretin gel in August 2000. For the first nine months of 2000, product sales were $16.2 million compared to
$9.1 million for the same period in 1999.
Sales of Targretin capsules doubled to $2.4 million during third quarter over second quarter and further accelerated its new patient
prescription adoption rate with nearly 250 new patient prescriptions in September alone. Refill prescriptions grew more than 67%
during the third quarter as existing patients continued their Targretin therapy. Physicians continue to explore Targretin dosage in both
monotherapy and combination regimens and in applications beyond CTCL.
Targretin gel launch was initiated during the third quarter and built solidly upon the Targretin capsule franchise with sales of $0.7
million and nearly 150 new patient prescriptions in September alone, its first full month of sales. The combined sales of Targretin
capsules and gel of $3.1 million exceeded that of ONTAK for the first time in third quarter.
ONTAK sales were largely stable during the third quarter but began to show signs of return to growth by the end of the quarter as
physicians began to clarify the relevant roles of both ONTAK and Targretin in their patient populations. During the quarter, some
physicians also began using combinations of ONTAK and Targretin in CTCL. These trends should facilitate a return to growth of
ONTAK sales in fourth quarter going forward.
Collaborative research and development and other milestone revenues were $5.6 million in the third quarter 2000 versus $6.3 million
in the third quarter 1999, and $18.3 million in the first nine months of 2000 versus $17.5 million in the first nine months of 1999.
Milestone and other revenues are expected to accelerate during fourth quarter.
Research and development expenses were $13.2 million in the third quarter 2000, a decrease of $2.5 million, or 16%, from $15.7
million in the third quarter 1999. In the first nine months of 2000, R&D expenses were $38.5 million versus $44.8 million in the prior
year, a decrease of $6.3 million or 14%. The decreases reflect a reduction in expenses for research and development associated with
the completion of the NDA for Targretin capsules in June 1999 and for Targretin gel in December 1999.
Selling, general and administrative expenses were $8.6 million in the third quarter 2000 compared to $6.0 million in the third quarter
1999, and $25.9 million in the first nine months of 2000 versus $20.1 million in the same period of 1999. The increases are
attributable to expansion of sales and marketing activities for Targretin capsules and Targretin gel launches and the continued
marketing of ONTAK and Panretin gel.
Loss from operations declined $3.2 million or 21% from $15.1 million in the third quarter 1999 to $12.0 million in the third quarter
2000 and declined $8.3 million or 19% from $44.6 million in the first nine months of 1999 to $36.2 million in the first nine months of
2000.
As of September 30, 2000, Ligand had cash, cash equivalents, short-term investments and restricted cash of $33.0 million versus
$49.2 million as of December 31, 1999. Under the terms of our strategic alliance with Elan, an additional $10 million in zero coupon
convertible notes are available to Ligand through December 31, 2000.
Web Cast Conference Call

Ligand Pharmaceuticals will host a live web cast, open to all interested parties, of a conference call during which David E. Robinson,
Ligand Chairman, President and CEO, and Paul V. Maier, Senior Vice President and Chief Financial Officer, will discuss earnings for
third quarter and the first nine months of 2000. The web cast will be available at http://www.streetevents.com and at
http://www.ligand.com (Investor/Public Relations page) on Tuesday, November 14, 2000, at 8:30 a.m. Eastern Standard Time.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of
patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis,
metabolic disorders and cardiovascular and inflammatory diseases. Ligand`s proprietary drug discovery and development programs
are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal
Transducers and Activators of Transcription (STATs).

This news release may contain certain forward-looking statements by Ligand which involve risks and uncertainties and reflect
Ligand`s judgement as of the date of this release. Actual events or results may differ from Ligand`s expectations. There can be no
assurance that results of subsequent clinical studies of Targretin capsules, ONTAK or any other Ligand or corporate partner product
will confirm earlier results, will be submitted to or approved by the FDA in a timely fashion or at all, or, if approved, such product will
be accepted by physicians for prescribing, by patients for use and by insurance companies/agencies for reimbursement. Additional
information concerning these and other risk factors affecting Ligand`s business can be found in prior press releases as well as in
Ligand`s public periodic filings with the Securities and Exchange Commission, available via Ligand`s website at
http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this
release.

Full prescribing information for Ligand`s products may be obtained in the U.S. from Ligand Professional Services by calling toll free
800-964-5836 or on Ligand`s web site at http://www.ligand.com.

Ligand Pharmaceuticals` releases are available on the World Wide Web at www.businesswire.com/cnn/lgnd.htm.



LIGAND PHARMACEUTICALS INCORPORATED
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)

Three Months Ended Nine Months Ended
Sept. 30, Sept. 30,
------------------ -------------------
2000 1999 2000 1999
---- ---- ---- ----
Revenues:
Product sales $ 6,477 $ 2,830 $ 16,234 $ 9,127
Collaborative
research and
development
and other
revenues 5,593 6,279 18,277 17,456
Contract
manufacturing -- 656 -- 1,884
-------- -------- -------- --------
Total revenues 12,070 9,765 34,511 28,467
-------- -------- -------- --------

Operating costs
and expenses:
Cost of
products sold 2,238 1,027 6,328 2,997
Contract
manufacturing -- 2,136 -- 5,180
Research and
development 13,229 15,717 38,480 44,799
Selling, general
and administrative 8,560 6,015 25,938 20,056
-------- -------- -------- --------
Total operating
costs and
expenses 24,027 24,895 70,746 73,032
-------- -------- -------- --------

Loss from
operations (11,957) (15,130) (36,235) (44,565)

Interest income 645 623 2,072 1,894
Interest expense (3,221) (3,551) (9,885) (8,942)
Debt conversion expense -- -- (2,025) --
Other, net (393) (248) (267) (245)
-------- -------- -------- --------
Net loss $(14,926) $(18,306) $(46,340) $(51,858)
======== ======== ======== ========

Basic and
diluted net
loss per share $ (0.26) $ (0.39) $ (0.84) $ (1.11)
======== ======== ======== ========
Shares used in
computing net
loss per share 56,605 47,476 55,341 46,580
======== ======== ======== ========


CONSOLIDATED BALANCE SHEETS
(in thousands)

Sept. 30, Dec. 31,
2000 1999
-------------- --------
Assets
Current assets:
Cash, cash equivalents and
short-term investments $ 31,562 $ 47,155
Other current assets 12,474 9,524
--------- ---------
Total current assets 44,036 56,679
Restricted investments 1,434 2,011
Property and equipment, net 11,784 20,542
Acquired technology, net 41,685 38,969
Other assets 16,072 16,444
--------- ---------
$ 115,011 $ 134,645
========= =========
Liabilities and Stockholders`
Deficit
Current liabilities $ 22,455 $ 20,701
Accrued acquisition obligation 2,700 2,900
Long-term portion of equipment
financing obligations 5,305 6,907
Convertible debentures and notes 114,891 129,727
Stockholders` deficit (30,340) (25,590)
--------- ---------
$ 115,011 $ 134,645
========= =========

[reed]

Huhu gibts denn ausser mir noch andere LGND Aktionäre??


BW0137 JAN 22,2001 5:16 PACIFIC 08:16 EASTERN



( BW)(CA-LIGAND-PHARMACEUTICALS)(LGND) Results Show ONTAK Produces Meaningful Responses in Advanced-Stage, Heavily Pre-Treated Patients with CTCL

Business Editors & Health/Medical Writers
BIOWIRE2K

SAN DIEGO--(BW Health Wire)--Jan. 22, 2001--

Pivotal Study Results Published in the Journal of Clinical Oncology

ONTAK(R) (denileukin diftitox) has been shown to induce substantial and durable partial and complete responses (30% response overall) in patients with persistent or refractory cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor and who have had extensive previous treatment. The results were just published in the Journal of Clinical Oncology.
A novel cytotoxic biologic from a new class of fusion proteins, ONTAK consists of a fragment of diphtheria toxin genetically fused to interleukin-2 (IL-2) which targets IL-2 receptors (IL-2R) on the surface of malignant cells that express CD25. The diphtheria toxin is then incorporated into the cell, inhibiting protein synthesis and resulting in cell death.
"ONTAK is an important new agent for patients with advanced or recurrent CTCL, particularly those in whom there is a high degree of symptomatology and disfigurement," said Elise A. Olsen, M.D., Professor of Medicine and Director of the Duke Cutaneous T-cell Lymphoma Clinic, Duke University Medical Center, Durham, NC. "Because myelosuppression is an uncommon effect, ONTAK may be particularly useful in patients with compromised marrow reserves as a result of previous radiation or multi-agent chemotherapy."
The multicenter, randomized, blinded, parallel-group study was the first Phase III trial conducted to evaluate the efficacy, safety and pharmacokinetics of two dose levels of ONTAK in CTCL patients whose malignant cells express the CD25 component of the IL-2 receptor. These data were the basis for the New Drug Application submitted in August 1998 and the accelerated approval in February 1999. ONTAK is marketed by Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) on behalf of its subsidiary, Seragen, Inc.
"The responses achieved in this trial with ONTAK become more impressive when you consider that, overall, 63% of these heavily pre-treated patients (who had received a median of five previous therapies) had advanced-stage CTCL," notes Steven D. Reich, M.D., Senior Vice President of Clinical Research at Ligand.
Patients with biopsy-proven CTCL that expressed CD25 on at least 20% of lymphocytes were assigned to one of two dose levels (9 or 18(mu)g/kg/d) of ONTAK administered five consecutive days every three weeks for up to eight cycles. Patients were monitored for toxicity and clinical efficacy, the latter assessed by changes in disease burden and quality of life measurements. Antibody levels of ONTAK and anti-IL-2 serum concentrations of ONTAK also were measured.
Overall, 21 out of 71 CTCL patients treated with ONTAK (30%) had an objective response (20% partial response; 10% complete response). The response rate and duration of response based on the time of first dose for all responders (median of 6.9 months with a range of 2.7 to greater than 46.1 months) were not statistically different between the two doses. There was, however, a trend suggesting a dose-effect for those patients with more advanced disease: an objective response was seen in 2/21 (10%) and 9/24 (38%) in patients with at least stage IIb disease treated with 9 or 18(mu)g/kg/d, respectively. Fifty-three of the 71 patients entered had significant pruritus at baseline and 36 (68%) of these had clinically significant improvement, an important factor in the quality of life for these patients.
In addition, the authors concluded that further research is needed into whether CD25 constitutes an adequate screen for likelihood of response to ONTAK. In this study, only 58% of all CTCL patient skin samples screened for inclusion had at least 20% of cells expressing CD25. However, 14 out of 32 patients (44%) showed variable results in CD25 expression from multiple biopsies taken from different anatomical sites on different days. It is uncertain whether this variability is biologic or a result of the inherent insensitivity of the screening assay. Moreover, it is unclear whether patients with less than 20% CD25 expression may benefit from ONTAK. Three of seven enrolled in this study had multiple skin biopsy samples showing variable CD25 expression and responded to treatment as did five of 11 responders (45%) who relapsed and were found to have low to nondetectable CD25 expression on post-treatment biopsies.
Adverse events consisted of flu-like symptoms (95%) (fever/chills, nausea/vomiting and myalgias/arthralgias), acute infusion-related events (60%) (hypotension, dyspnea, chest pain, and back pain), and vascular leak syndrome (25%) (hypotension, hypoalbuminemia, edema). In addition, 61% of patients experienced transient elevations of hepatic transaminase levels with 17% Grade 3 or 4. Hypoalbuminemia occurred in 79%, including 15% with Grade 3 or 4 changes. Tolerability at 9 and 18 (mu)g/kg/d was similar. It should be noted that systemic corticosteroids as premedication or concomitant medication during infusion of ONTAK were prohibited.

Cutaneous T-Cell Lymphoma (CTCL)

Affecting an estimated 16,000 people in the U.S. and between 12,000 and 14,000 people in Europe, CTCL is a cancer of T-lymphocytes (white blood cells involved in the body`s immune system). T-cell lymphomas, of which CTCL is a subclass, represent approximately 10% of the non-Hodgkin`s lymphomas (NHL), which affect approximately 300,000 individuals in the U.S. CTCL ordinarily manifests itself initially in the skin, but over time may progress to involve other organs. CTCL is most commonly a slowly progressing cancer, and many patients live with the complications of CTCL for 10 or more years after diagnosis. Some patients, however, have a much more aggressive form of this disease.

ONTAK(R)

In February 1999, the U.S Food and Drug Administration (FDA) granted Seragen, Inc., a wholly owned subsidiary of Ligand, marketing approval for ONTAK(R) for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor. The safety and efficacy of ONTAK in patients whose malignant cells do not express the CD25 component of the IL-2 receptor have not been examined. ONTAK, a fusion protein, consists of a fragment of diphtheria toxin genetically fused to IL-2. ONTAK targets IL-2 receptors on the surface of malignant cells and the diphtheria toxin is rapidly incorporated through endocytosis, killing the cell within hours. Phase II clinical trials also are underway to evaluate ONTAK for the treatment of patients with low- and intermediate-grade non-Hodgkin`s lymphoma, chronic lymphocytic leukemia, and severe psoriasis.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. Ligand`s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).

This news release may contain certain forward-looking statements by Ligand which involve risks and uncertainties and reflect Ligand`s judgment as of the date of this release. Actual events or results may differ from Ligand`s expectations. There can be no assurance that final results will be consistent with results from large-scale clinical trials or that clinical trial results in additional indications will be supportive of regulatory approvals required to market ONTAK for treatment in the additional indications. Additional information concerning these and other risk factors affecting Ligand`s business can be found in prior press releases as well as in Ligand`s public periodic filings with the Securities and Exchange Commission, available via Ligand`s website at http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Full prescribing information for Ligand`s products may be obtained in the U.S. from Ligand Professional Services by calling toll-free 800-964-5836 or on Ligand`s web site at http://www.ligand.com.

Ligand Pharmaceuticals` releases are available on the World Wide Web at www.businesswire.com/cnn/lgnd.htm.


--30--dw/sd* js/sd

CONTACT: Ligand Pharmaceuticals Incorporated, San Diego
Christiane V. Sheid, 858/550-7809
Vice President Finance & Communications

KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL

[JoeUp]

Hallo reed,

ich bin noch drin. LGND wurde wenigsten nicht so gebeutelt
wir andere Pharmas und da ich bei 8 eingestiegen bin und noch
einiges erwarte, bleibe ich auch drin!

JoeUp